1,4-Diaminobutanedihydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,4-Diaminobutanedihydrochloride
• 英文别名: butane-1,4-diamine;hydron;dichloride
• 化学式: C4H14Cl2N2
• 分子量: 161.07
• InChiKey: XXWCODXIQWIHQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.53
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  4
• 氢受体数：
  2

ADMET

毒理性

• 副作用

职业性肝毒素 - 第二性肝毒素：在职业环境中的毒性效应潜力是基于人类摄入或动物实验的中毒病例。

Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

反应信息

• 作为反应物：
  描述：

  [(1S,8S)-5-tritio-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-1-yl]methanol 、 1,4-Diaminobutanedihydrochloride 生成 isoechinatine
  参考文献：
  名称：

  KUNEC, ELLEN K.;ROBINS, DAVID J., J. CHEM. SOC. PERKIN TRANS. PT 1,(1989) N, C. 1437-1441

  摘要：

  DOI：
• 作为产物：
  描述：

  丁二腈 以95的产率得到1,4-Diaminobutanedihydrochloride
  参考文献：
  名称：

  Org. Lett. 2019, 21, 287-291

  摘要：

  DOI：
• 作为试剂：
  描述：

  5-chloromethylimidazo[1,2-a]pyridine hydrochloride 、 四亚甲基二胺 、 、 五氟丙酸 、 三乙胺 在 1,4-Diaminobutanedihydrochloride 、 二氯甲烷 、 saturated aqueous saline solution 、 magnesium sulfate 、 silica gel 、 甲醇 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以to afford 13.61 g of the desired compound (53.6%的产率得到5-[N-(4-pentafluoropropionamidobutan-1-yl)aminomethyl]imidazo[1,2-a]pyridine
  参考文献：
  名称：

  Tricyclic compounds, their production and use

  摘要：

  式子1中的三环化合物：其中环A是含有两个氮原子作为杂原子的含氮杂环，可选择性地用氧代或硫代取代; 环Q可以选择性地被取代; Y是可选择性取代的碳氢基团，可选择性取代的羟基或可选择性取代的巯基，但不包括甲基基团作为Y; R1是氢原子，卤素原子，可选择性取代的碳氢基团或酰基，或其盐，具有优异的PDGF抑制活性，降压活性，改善肾脏疾病活性和降低脂质水平活性。

  公开号：

  US20010051631A1

文献信息

• AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20200377461A1

  公开（公告）日：2020-12-03

  An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.

  一种氨基化合物，用作半羧酸敏感性氨基氧化酶（SSAO）和/或血管粘附蛋白-1（VAP-1）抑制剂，一种药物组合物，以及其在药物中的应用，可用于治疗炎症和/或与炎症相关的疾病，糖尿病和/或与糖尿病相关的疾病，精神障碍，缺血性疾病，血管疾病，纤维化或组织移植排斥。
• ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：Moorman Allan R.

  公开号：US20080242672A1

  公开（公告）日：2008-10-02

  The present invention provides compounds of the formula wherein R 1 and R 2 have meaning as defined herein in the specification. The compounds of formula (I) are adenosine A 2A receptor antagonists and, thus, may be employed for the treatment of conditions and diseases mediated by the adenosine A 2A receptor activity. Such conditions include, but are not limited to, diseases of the central nervous system such as depression, cognitive function diseases and neurodegenerative diseases such as Parkinson's disease, senile dementia as in Alzheimer's disease or psychoses and stroke. The compounds of the present invention may also be employed for the treatment of attention related disorders such as attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD), extra pyramidal syndrome, e.g., dystonia, akathisia, pseudoparkinsonism and tardive dyskinesia, and disorders of abnormal movement such as restless leg syndrome (RLS) and periodic limb movement in sleep (PLMS); cirrhosis, and fibrosis and fatty liver; dermal fibrosis in diseases such as scleroderma; and the mitigation of addictive behavior. In particular, the compounds of the present invention may be employed to improve motor-impairment due to neurodegenerative diseases such as Parkinson's disease.

  本发明提供了以下式的化合物 其中R 1 和R 2 的含义如规范中所定义。式(I)的化合物是腺苷A 2A 受体拮抗剂，因此可用于治疗由腺苷A 2A 受体活性介导的疾病和病症。这些疾病包括但不限于中枢神经系统疾病，如抑郁症、认知功能疾病和神经退行性疾病，如帕金森病、老年性痴呆症、精神病和中风。本发明的化合物还可用于治疗注意力相关障碍，如注意力缺陷障碍（ADD）和注意力缺陷多动障碍（ADHD），额外锥体综合征，例如肌张力障碍、不安坐立、假性帕金森症和迟发性运动障碍，以及异常运动障碍，如不宁腿综合征（RLS）和睡眠中期肢体运动（PLMS）；肝硬化、纤维化和脂肪肝；在硬皮病等疾病中的皮肤纤维化；以及对成瘾行为的缓解。特别是，本发明的化合物可用于改善由帕金森病等神经退行性疾病引起的运动障碍。
• [EN] COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS<br/>[FR] COMPOSÉS UTILES POUR LE TRAITEMENT DE TROUBLES DU TRACTUS DIGESTIF
  申请人：ARDELYX INC

  公开号：WO2018129552A1

  公开（公告）日：2018-07-12

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗与液体潴留或盐过多有关的疾病的方法，例如心力衰竭（特别是充血性心力衰竭）、慢性肾病、晚期肾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂诱导的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• [EN] FLOW CHEMISTRY SYNTHESIS OF ISOCYANATES<br/>[FR] SYNTHÈSE CHIMIQUE EN FLUX D'ISOCYANATES
  申请人：UNIV CALIFORNIA

  公开号：WO2021119606A1

  公开（公告）日：2021-06-17

  The disclosure provides, inter alia, safe and environmentally-friendly methods, such as flow chemistry, to synthesize isocyanates, such as methylene diphenyl diisocyanate, toluene diisocyanate, hexamethylene diisocyanate, isophorone diisocyanate, and tetramethylxylene diisocyanate.

  该披露提供了诸如流动化学等安全环保的方法，用于合成异氰酸酯，例如亚甲基二苯基二异氰酸酯、甲苯二异氰酸酯、己二胺二异氰酸酯、异佛尔酮二异氰酸酯和四甲基二异氰酸酯。
• Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
  申请人：Collins A. Douglas

  公开号：US20060074034A1

  公开（公告）日：2006-04-06

  This invention is in the area of cobalamin-mediated delivery of nucleic acids and analogs and derivatives thereof to a host to affect gene expression.

  这项发明涉及钴胺素介导的核酸及其类似物和衍生物的传递到宿主以影响基因表达。

表征谱图